Psyence Biomedical Ltd. (PBMWW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Peers in industry
Psyence Biomedical Ltd. has no peer companies in this window.
Recent press releases
April 2026
Psyence Biomedical PBM Doses First Patient in Phase IIb Trial for NPX-5
# 🧾 What This Document Is This is a **6-K filing**, which is a report a foreign company (like this one, based in New York but listed on Nasdaq) files with the SEC to announce major news. It contains a **press release** from Psyence Biomedical announcing they've started giving their investigational
SEC filings
All filings →Insider trades
All insider trades →Psyence Biomedical Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Psyence Biomedical Ltd.
All people →No officers or directors have been indexed for Psyence Biomedical Ltd..